Silo Pharma announced it received a Notice of Allowance from the U.S. Patent Office for its SPC-15 therapeutic, targeting PTSD. This signifies that the patent will be granted shortly, strengthening the company's intellectual property for a key drug candidate.
Silo Pharma has received a Notice of Allowance from the U.S. Patent Office for its SPC-15 therapeutic, which is designed to prevent stress-induced behavioral responses related to PTSD. This is a significant step as it confirms the patentability of their invention, including both composition and method claims, and indicates the patent will be formally issued soon. This development strengthens Silo Pharma's intellectual property portfolio, which is crucial for biopharmaceutical companies as it protects their innovations and provides a competitive advantage. For traders, this is a moderately positive long-term development for SILO, as it de-risks the development of SPC-15 and enhances the company's asset value, though the immediate market impact might be limited given it's an expected step in drug development rather than a clinical trial breakthrough.